Neurol. praxi. 2021;22(3):231-234 | DOI: 10.36290/neu.2021.038

Treatment persistence to ocrelizumab and local experience

MUDr. Simona Halúsková, prof. MUDr. Martin Vališ, Ph.D., FEAN
Neurologická klinika LF UK a FN Hradec Králové

Multiple sclerosis (MS) is a chronic inflammatory autoimmune and neurodegenerative disease of the central nervous system affecting most commonly young adults. There has been tremendous progress in the treatment of MS over recent years. Ocrelizumab is a humanized monoclonal antibody that causes selective depletion of CD20+ B-lymphocytes. The drug has shown its efficacy in treating both relapsing-remitting and primary progressive MS. Medication adherence and persistence play an essential role in the treatment of MS. Adherence to treatment fundamentally contributes to optimal therapeutic outcomes, improved patients' quality of life and reduced healthcare costs. Adherence should be constantly promoted in routine clinical practice.

Keywords: multiple sclerosis, treatment, ocrelizumab, adherence, persistence.

Received: May 20, 2021; Revised: May 20, 2021; Accepted: May 24, 2021; Prepublished online: May 24, 2021; Published: October 1, 2021  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Halúsková S, Vališ M. Treatment persistence to ocrelizumab and local experience. Neurol. praxi. 2021;22(3):231-234. doi: 10.36290/neu.2021.038.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Butzkueven H, Spelman T, Ozakbas S, Kalincik T, Boz C, Buzzard K, Skibina O, Alroughani R, Karabudak R, Van Der Walt A, Lechner-Scott J, Hodgkinson S, Laureys G, Van Hijfte L, Terzi M, Butler E, Macdonell R, Patti F, Van Pesch V, Slee M, Barnett M, Grammond P, Prevost J, Grand-Maison F, Taylor B, Kermode A, McCombe P, Duquette P, Prat A, Girard M, Eichau Madueño S, Izquierdo G, Soysal A, Sánchez-Menoyo JL, Sotoca J, Muros-Le Rouzic E, Dirks P. Real-world experience with Ocrelizumab in the MSBase Registry. ACTRIMS-ECTRIMS 2020, P0909.
    2. Engmann NJ, Sheinson D, Bawa K, Ng CD, Pardo G. Persistence and adherence to ocrelizumab compared with other disease-modifying therapies for multiple sclerosis in U.S. commercial claims data [ahead of print]. J Manag Care Spec Pharm 2021; 1-11. Go to original source... Go to PubMed...
    3. Gelfand JM, Cree BAC, Hauser SL. Ocrelizumab and other CD20+ B-cell-depleting therapies in multiple sclerosis. Neurotherapeutics 2017; 14: 835-841. Go to original source... Go to PubMed...
    4. Giovannoni G. The neurodegenerative prodrome in multiple sclerosis. Lancet Neurol 2017; 16: 413-414. Go to original source... Go to PubMed...
    5. Hauser SL, Bar-Or A, Comi G, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Montalban X, Rammohan KW, Selmaj K, Traboulsee A, Wolinsky JS, Arnold DL, Klingelschmitt G, Masterman D, Fontoura P, Belachew S, Chin P, Mairon N, Garren H, Kappos L; OPERA I and OPERA II Clinical Investigators. Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. N Engl J Med 2017; 376: 221-234. Go to original source... Go to PubMed...
    6. Hauser SL, Brochet B, Montalban X, Naismith RT, Wolinsky JS, Manfrini M, Garas M, Villoslada P, Model F, Hubeaux S, Kappos L. Long-term reduction of relapse rate and confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. ECTRIMS 2018, P590. Go to original source...
    7. Hauser SL, Kappos L, Montalban X, Chognot C, Craveiro L, Pradhan A, Prajapati K, Wolinsky JS. Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. ACTRIMS-ECTRIMS 2020, P0389. Go to original source...
    8. https://www.ocrelizumabinfo.global/en/homepage.html (accessed 24 March 2021).
    9. Jakimovski D, Vaughn CB, Eckert S, Zivadinov R, Weinstock--Guttman B. Long-term drug treatment in multiple sclerosis: safety success and concerns. Expert Opin Drug Saf 2020; 19: 1121-1142. Go to original source... Go to PubMed...
    10. Juanatey A, Blanco-Garcia L, Tellez N. Ocrelizumab: its efficacy and safety in multiple sclerosis. Rev Neurol 2018; 66: 423-433. Go to original source...
    11. Klotz L, Havla J, Schwab N, Hohlfeld R, Barnett M, Reddel S, Wiendl H. Risks and risk management in modern multiple sclerosis immunotherapeutic treatment. Ther Adv Neurol Disord 2019; 12: 1756286419836571. Go to original source... Go to PubMed...
    12. Lizán L, Comellas M, Paz S, Poveda JL, Meletiche DM, Polanco C. Treatment adherence and other patient-reported outcomes as cost determinants in multiple sclerosis: a review of the literature. Patient Prefer Adherence 2014; 8: 1653-1664. Go to original source... Go to PubMed...
    13. Meuth S, Buttmann M, Weber MS, Dirks P, Eggebrecht J, Joschko N, Leemhuis J, Martinec M, Muros-Le Rouzic E, Zalocusky KA, Ziemssen T. Treatment persistence and adherence to ocrelizumab in the real-world setting - an ad-hoc analysis of the CONFIDENCE study. ACTRIMS-ECTRIMS 2020, P1063.
    14. Montalban X, Hauser SL, Kappos L, Arnold DL, Bar-Or A, Comi G, de Seze J, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Rammohan KW, Selmaj K, Traboulsee A, Sauter A, Masterman D, Fontoura P, Belachew S, Garren H, Mairon N, Chin P, Wolinsky JS; ORATORIO Clinical Investigators. Ocrelizumab versus placebo in primary progressive multiple sclerosis. N Engl J Med 2017; 376: 209-220. Go to original source... Go to PubMed...
    15. Oh J, Vidal-Jordana A, Montalban X. Multiple sclerosis: clinical aspects. Curr Opin Neurol 2018; 31: 752-759. Go to original source... Go to PubMed...
    16. Wolinsky JS, Vermersch P, Hartung HP, Naismith RT, Airas L, Coutant K, Koendgen H, Schneble HM, Overell J, Sauter A, Prajapati K, Kappos L. Sustained reduction in 48-week confirmed disability progression in patients with PPMS treated with ocrelizumab in the ORATORIO OLE: 7-year follow-up. ACTRIMS-ECTRIMS 2020, P0237.

    Return to the content


    Neurology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.